Abstracts tagged "Antibiotics"

Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
Stephen Wong¹, Amy Gaultney ² and Deborah McCurdy ³, ¹University of California Los Angeles, Los Angeles, California, ²UCLA, Los Angeles, California, ³UCLA Medical Center, Los Angeles, California
Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…
Abstract Number: 1220 • 2018 ACR/ARHP Annual Meeting
The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis
Lior Nissim¹, Mary Louise Fowler², Robert Shmerling³, Sarah Lieber⁴, Mohammad Naffaa⁵ and Ziv Paz^4,5, ¹Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, ²Boston University School of Medicine, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Galilee Medical Center, Nahariya, Israel
Background/Purpose: Approximately 20,000 cases of septic arthritis (SA) occur in the United States each year with 2-10 cases per 100,000 person-years in the general population.…
Abstract Number: 1238 • 2018 ACR/ARHP Annual Meeting
The Effect of Antibiotic Therapy on Positive Culture Results Among Patients with Prosthetic Joint Septic Arthritis
Efrat Gur Rosset¹, Mary Louise Fowler², Sarah Lieber³, Robert Shmerling⁴ and Ziv Paz^3,5,6, ¹Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, ²Boston University School of Medicine, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁵Galilee Medical Center, Nahariya, Israel, ⁶Azrieli Faculty of Medicine, Bar-Ilan University, Sefad, Israel
Background/Purpose: Little is known about the effects of antibiotic therapy on synovial and blood culture results among patients with prosthetic joint septic arthritis (PJSA). In…
Abstract Number: 1915 • 2016 ACR/ARHP Annual Meeting
Partial Elimination of Intestinal Microbiota Dampens T Helper 17 Cell Differentiation and Established Collagen-Induced Arthritis in Mice
Rebecca Rogier¹, Heather Evans-Marin², Birgitte Walgreen¹, Monique M. Helsen¹, Liduine van den Bersselaar¹, Peter M. van der Kraan¹, Fons A.J. van de Loo³, Peter L. van Lent¹, Jose U. Scher⁴, Wim B. van den Berg¹, Marije I. Koenders¹ and Shahla Abdolahi-Roodsaz¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴New York University School of Medicine, New York, NY
Background/Purpose: High-throughput sequencing of intestinal microbiota recently revealed that the composition of intestinal microbiota is perturbed in patients with new onset untreated rheumatoid arthritis (RA).…
Abstract Number: 1345 • 2015 ACR/ARHP Annual Meeting
The Impact of Prior Antibiotic Treatment on Culture Results of Patients with Septic Arthritis
Ziv Paz¹, Sarah B. Lieber¹, Andrew Moore², Clara Zhu³, Mary Louise Fowler⁴ and Robert H. Shmerling⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, ³Medical School, Boston University School of Medicine, Boston, MA, ⁴School of Medicine, Boston University School of Medicine, Boston, MA, ⁵Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Synovial fluid culture and gram stain offer the most compelling proof of septic arthritis (SA); these tests are indicated in every suspected case. However,…
Abstract Number: 1927 • 2015 ACR/ARHP Annual Meeting
Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc
Peter J. Wermuth¹ and Sergio A. Jimenez², ¹Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Activated myofibroblasts are the primary mediators of the excessive synthesis and deposition of collagens and other extracellular matrix (ECM) macromolecules during the pathogenesis of…
Abstract Number: 2823 • 2015 ACR/ARHP Annual Meeting
Gut Inflammation in HLA-B27 Transgenic Rats Alters the Monocyte Compartment and Its Osteoclastogenic Potential
C. Ansalone, L. Utriainen, S. W. F. Milling and C. S. Goodyear, Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Human HLA-B27 and β2-microglobulin transgenic rats (B27 rats), an animal model for spondyloarthropathies, spontaneously develop inflammatory colitis and bone loss. We have previously demonstrated…
Abstract Number: 2740 • 2014 ACR/ARHP Annual Meeting
Microbiota Modulate Intraepithelial Lymphocyte Presence and Function
Kristine A. Kuhn and Sean P. Colgan, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Microbiome studies in autoimmune diseases including rheumatoid arthritis and inflammatory bowel disease demonstrate alterations in relative abundance of specific bacterial species (dysbiosis). The immunologic…
Abstract Number: 929 • 2014 ACR/ARHP Annual Meeting
Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study
Daniel B. Horton^1,2, Frank I. Scott IV^1,3, Kevin Haynes¹, Mary E. Putt¹, Carlos D. Rose², James D. Lewis^1,3 and Brian L. Strom^1,4, ¹Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, ³Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Dysregulation of the human microbiome has been implicated in the development of several autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). Moreover,…
Abstract Number: 856 • 2014 ACR/ARHP Annual Meeting
A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus
Silvio M. Vieira¹, Andrew Yu¹, Michael Hiltesperger¹, Odelya E. Pagovich¹, Eleni Tiniakou¹, William Ruff², John Sterpka¹ and Martin Kriegel^2,3, ¹Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, New Haven, CT, ³Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The etiology of lupus-associated antiphospholipid syndrome (APS) is unknown but microbial triggers have been implicated in transient antiphospholipid antibody production in both mice and…
Abstract Number: 2807 • 2013 ACR/ARHP Annual Meeting
Management Of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus 12 Weeks Of Antibiotic Treatment
Louis Bernard¹, Aurélien Dinh², Idir Ghout³, Valérie Zeller⁴, Bertrand Issartel⁵, Nadia Belmatoug⁶, Michel Dupon⁷ and Denis Mulleman⁸, ¹University hospital of Tours, Tours, France, ²University hospital of Paris, Garches, France, ³Biostatistic, University Hospital of Paris, Boulogne, France, ⁴Internal medicine, La Croix Saint Simon Hospital, Paris, France, ⁵Clinique du Tonkin, Lyon, France, ⁶University hospital of Paris, Clichy, France, ⁷infectious disease, University Hospital of Bordeaux, Bordeaux, France, ⁸CHU Trousseau Tours, Tours, France
Background/Purpose: As for most of bone and joint infection, optimal treatment duration for vertebral osteomyelitis (VO) is unknown. In an era of increasing bacterial resistance,…
Abstract Number: 556 • 2013 ACR/ARHP Annual Meeting
Depletion Of The Gut Microbiota Prevents β₂-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome
Silvio M. Vieira¹, Andrew Yu¹, Odelya E. Pagovich¹, Eleni Tiniakou², John Sterpka¹ and Martin A. Kriegel^3,4, ¹Yale School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production…
Abstract Number: 172 • 2012 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis
Claire E. Barber¹, Joseph Kim², Robert D. Inman³, John Esdaile⁴ and Matthew T. James⁵, ¹Rheumatology, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, Canada, ³Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Medicine, Univeristy of Calgary, Calgary, Canada
Background/Purpose: Although bacterial infections are a common precipitant, it is unclear whether antibiotic treatment is effective for reactive arthritis. The purpose of this study was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].